The evaluation for usefulness of dienogest to prevent decline of ovarian reserve by cystectomy for endometriomas

The evaluation for usefulness of dienogest to prevent decline of ovarian reserve by cystectomy for endometriomas - The evaluation for usefulness of dienogest to prevent decline of ovarian reserve by cystectomy for endometriomas.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018569

Enrollment

Registered

2015-10-01

Start date

2016-03-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometrioma

Interventions

dienogest 2mg/day, 8 weeks before operation and 8 weeks after operation buserelin acetate 1.8mg/every 4 weeks, twice before operation and twice after operation

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: unilateral or bilateral endometrioma(s) with 4-cm diameter at least

Exclusion criteria

Exclusion criteria: Hisory of ovarian surgery, History of hormonal therapy within 6 months before surgery, Complication with other endocrinological diseases

Design outcomes

Primary

Measure	Time frame
Serum concentrations of AMH, 2 and 1 months before operation, 1,2,6,12 months after operation	—

Countries

Japan

Contacts

Public ContactSatoko Osuka

Nagoya University Hospital Maternal and Perinatal Medicine

satokoosuka@med.nagoya-u.ac.jp0527442261

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026